Infection of rat RT2 glioma cells in vitro with an adenovirus (ADV-TK) expressing herpes simplex virus (HSV) thymidine kinase (TK) and subsequent exposure to 5-bromo-2Ј-deoxycytidine (BrdC), which is specifically incorporated into ADV-TK-infected cell DNA as 5-bromo-2Ј-deoxyuridine (BrdU), results in significant radiosensitization (sensitizer enhancement ratio: 1.4 -2.3) compared with Ad␤gal-infected cells. Cell killing correlated well with increased BrdU DNA incorporation and with apoptosis. Whereas radiation (4 Gy) alone was relatively ineffective in inducing apoptosis, treatment with HSV-TK/BrdC resulted in BrdC dose-(10 -100 M) and time-dependent (24 -48 hours) increases, and the combination of the two treatments produced a synergistic response (1.5-to 2-fold). To investigate the effects of the ADV-TK/BrdC treatment in vivo, RT2 cells were grown as soft tissue tumors in Fischer 344 rats and conditions for virus infusion were optimized by altering the volume and rate of infusion using a rate-controlled positive pressure device. We found that relatively large volumes (100 -150 L) of virus delivered at rates of Յ1 L/minute were optimal and gave uniform and reproducible results. Using these optimal infusion conditions, we were able to achieve 40% adenovirus infection in the tumor. Infection of RT2 tumors with ADV-TK and continuous administration of BrdC from an osmotic pump resulted in significant (.001 Ͻ P Ͻ .009) tumor regression 6 days after radiation (30 Gy delivered as 2 ϫ 5 Gy over 3 days) compared with controls. In situ staining of sectioned tumors with anti-BrdU antibody or by high-performance liquid chromatography analysis of extracted and hydrolyzed tumor DNA confirmed that we obtained efficient and specific incorporation of BrdU into tumor cells. These results suggest that adenovirus-mediated delivery of HSV-TK in combination with BrdC and radiation can potentially be an efficient combination modality for the treatment of gliomas. Cancer Gene Therapy (2000) 7, 778 -788 Key words: Cancer gene therapy; drug delivery; halogenated pyrimidines; osmotic pump; radiation.
T he halogenated pyrimidines (HPs) 5-bromo-2Ј-deoxyuridine (BrdU) and 5-iodo-2Ј-deoxyuridine (IdU) have been studied extensively as radiosensitizers of various mammalian cells in culture. [1] [2] [3] Preclinical and clinical studies have revealed that both BrdU and IdU are relatively efficient radiosensitizers if incorporated at sufficient levels into DNA. 4, 5 However, although some clinical success has been achieved with head and neck tumors, attempts to radiosensitize gliomas with HPs have been disappointing, perhaps due to poor incorporation of the halogenated nucleosides into the DNA of these types of tumor cells. 6 Therefore, improved or alternative approaches are needed to treat this disease. The thymidine kinase (tk) gene of herpes simplex virus (HSV) has been used extensively to sensitize cancer cells to the HSV-TK-specific drug ganciclovir (GCV), and quite promising results with glioma have been obtained using various animal tumor models. 7, 8 Adenovirus delivery of the HSV tk gene in combination with GCV is undergoing clinical trials as a potential treatment for different types of cancers, including gliomas. 9 Here, we have explored the feasibility of using HSV-TK expressed from an adenovirus in combination with 5-bromo-2Ј-deoxycytidine (BrdC) to radiosensitize rat glioma cells in vitro and in vivo. We demonstrate that BrdC in combination with HSV-TK is an effective radiosensitizer in vitro that appears to kill cells primarily by apoptosis. We also show that efficient adenovirus infection of tumors can be achieved by slow, positive pressure infusion resulting in specific and efficient incorporation of BrdU into tumor cell DNA that results in significant tumor regression in combination with radiation.
MATERIALS AND METHODS

Cell culture
Rat glioma RT2 cells 10 derived from Fischer 344 rats (a kind gift of Dr. Randy Merchant, Department of Anatomy, Medical College of Virginia), were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine sera (FBS) supplemented with penicillin/streptomycin. For in vitro studies, infected cells were exposed to BrdC or BrdU that had been added to the medium to a final concentration of 10 or 100 M. Cells were irradiated in medium with a 60 Co ␥-irradiator set at 1.2 Gy/minute (Picker Zonegard V4 M60, Picker Manufacturing, Cleveland, Ohio). Cell viability was determined by either trypan blue dye exclusion or 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay. Statistical analysis was carried out by the unpaired, one-tailed Student's t test.
Adenovirus
ADV-TK (a kind gift of E. Nabel, University of Michigan, Ann Arbor, Mich) and Ad␤gal were grown in 293 cells as described previously 11 and purified by CsCl gradient centrifugation followed by dialysis against 13% glycerol in phosphate-buffered saline (PBS). Virus was snap frozen in liquid nitrogen and stored at Ϫ70°C until further use. Virus was titrated using a direct immunofluorescence assay (Light Diagnostics, Temacula, Calif) and standard virus plaque assay on 293 cells. We routinely achieve titers of 2 ϫ 10 11 plaque-forming units (PFU)/mL.
Apoptosis assays
Terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assays were carried out with an ApopTag Direct kit from Oncor (Gaithersburg, Md), according to the manufacturer's instructions, to provide a measurement of apoptosis. Alternatively, BrdC-or BrdUtreated RT2 cells were harvested in culture media containing 0.25% ethylenediaminetetraacetic acid (EDTA) and centrifuged onto glass slides. Cytocentrifuge preparations (ϳ30,000 cells/slide) were fixed in methanol for 10 minutes, stained with Giemsa, and viewed by phase contrast light microscopy for morphological characteristics of apoptosis. Percentages of apoptotic cells were determined by evaluating Ն300 cells/slide.
High-performance liquid chromatography (HPLC) analysis
Cell pellets were resuspended in lysis solution (10 mM tris(hydroxymethyl)aminomethane (Tris)-HCl, 140 mM NaCl, 1.5 mM MgCl 2 , and 0.5% Nonidet P-40 (pH 7.5)) and placed on ice for 5 minutes. Samples were then centrifuged, and the supernatant was discarded. Pellets were resuspended in 250 L of 10 mM Tris-HCl, 1 mM EPTA, pH 8.0 (TE) buffer to which 250 L of 2ϫ proteinase K buffer (0.2 M Tris-HCl, 25 mM EDTA, 0.3 M NaCl, 2% sodium dodecyl sulfate (pH 7.5)) and 100 g of proteinase K was added. Samples were incubated at 65°C for 2 hours and then briefly sonicated. After phenol/ CHCl 3 extraction, the samples were EtOH-precipitated and dried. Samples were boiled for 3 minutes in 100 L of TE buffer and treated with endonuclease P 1 (Pharmacia, Piscataway, NJ) in 30 mM NaOAc, 0.5 mM ZnSO 4 (pH 5.4) at 37°C for 2 hours. Tris-base and bacterial alkaline phosphatase (AP) (Sigma, St. Louis, Mo) were added and the reactions were incubated for another 2 hours at 37°C. Samples were finally extracted with phenol/CHCl 3 followed by ether and subsequently analyzed by HPLC. Samples were run isocratically on a C 18 reverse phase YMC ODS-AQ S-5 120A (4.6 ϫ 250 mm)
HPLC column (YMC, Wilmington, NC) with a flow rate of 0.7 mL/minute in 20 mM ammonium acetate (pH 3.5) for 5 minutes, followed by ramping for 8 minutes to 100% of 20 mM ammonium acetate with 5% methanol (pH 3.5), using a Beckman model 332 gradient liquid chromatograph system and a Beckman model 160 spectrometer (Beckman Instruments, Fullerton, Calif) set at 254 nm. For the cytidine deaminase (CD) assay, cell samples were freeze-thawed three times followed by centrifugation. Protein concentrations were determined by standard colorimetric assay (Pierce, Rockford, Ill) using bovine serum albumin as the standard. A total of 10 or 100 g of total protein extracts was assayed for 15 minutes at 37°C in 300 L of 50 mM Tris-HCl (pH 8.0), 1 mM EDTA, and 2 mM dithiothreitol with 6.7 M deoxycytidine and 0. 
Infusion and irradiation of tumors
All animal experimentation was approved by the Medical College of Virginia Institutional Animal Care and Use Committee as described in protocol no. 9603-2222. RT2 cells were suspended in PBS to give 1 ϫ 10 7 cells/mL. A total of 100 L of this suspension was injected into 10-to 12-week-old, 150 -160 g, female Fisher 344 rats. Animals were anesthetized and immobilized with one 0.15-cc intraperitoneal injection of a 5:1 (vol/vol) ketamine-HCl (100 mg/mL):rompun (100 mg/mL) mixture; next, after shaving, subcutaneous (s.c.) injections were made with aliquots of cells. Three sites were injected on each leg and five on each side of the back. When the average tumor size had reached 8 -10 mm in diameter, the tumors were infused with virus. Virus infusions were carried out by diluting Ad␤gal and ADV-TK and loading a 0.5-cc syringe that was assembled onto a BAS model MD-1001 Beehive pump (Bioanalytical Systems, West LaFayette, Ind) set at a flow rate of between 0.5 and 1 L/minute with a BAS model MD-1020 Beehive pump controller (Bioanalytical Systems). The virus was infused into the tumor center using a 5-cm long, 26-gauge needle. In those animals receiving osmotic mini-pumps (AL-ZET model 2 ML1, delivering 10 L/hour over 7 days; ALZA Scientific Products, Palo Alto, Calif), a small s.c. pocket on the back of each animal was made. Each pump was filled with ϳ2.2 mL of BrdC (50 mg/mL) and inserted; next, the wounds were closed with clamps. The animals were allowed to rest for 5 days to ensure expression of the adenovirus trans-gene, serum saturation of drug, and incorporation of BrdU into the tumor DNA before irradiation was begun. Animals were anesthetized and irradiated with 5 Gy (Picker Zonegard V4 M60 60 Co ␥-irradiator at 1.2 Gy/minute) in the morning and again in the afternoon. The diameters of each tumor were measured with calipers. Statistical analysis was performed using the Sidak multiple comparison procedure in a two-way factorial design. 12 
Tumor histology
Frozen sections of 20 m thickness were collected on poly-Llysine coated poly-Prep slides (Sigma) and allowed to dry at room temperature for 24 hours. For ␤-galactosidase (␤-gal) staining, sections were fixed on the slides in 3% paraformaldehyde/0.25% glutaraldehyde at 4°C for 10 minutes before being washed twice at room temperature with PBS for 10 minutes. Slides were immersed in staining buffer (0.5 mg/mL of 5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal) in 2 mM MgCl 2 , and 20 mM K 2 Fe(CN) 6 , 20 mM K 4 Fe(CH) 6 ⅐H 2 O (pH 7.3)) and placed in a 37°C incubator for 24 hours with gentle rocking. After staining, each slide was washed twice for 10 minutes in PBS before mounting. The stained area of each section was quantified and calculated as a percentage of the total cell surface area using an Olympus BH-2 microscope (Olympus, Melville, NY) and MCID M4 integration software from Imaging Research (St. Catherine's University, Ontario, Canada).
For analysis of BrdU incorporation, tumors were surgically excised, frozen, sectioned, and fixed as described above. DNA was denatured by treatment with 1 M HCl in a humidified chamber at 37°C for 30 minutes followed by washing in 10 mM Tris-HCl, 1 mM EDTA (pH 8) buffer. Blocking solution (0.02% Tween-20, 10% goat sera in PBS) was applied to each section for 30 minutes. The slides were removed and washed extensively in PBS before the mouse anti-BrdU antibody (Ab) solution (1:100; Becton Dickinson Immunocytometry Systems, San Jose, Calif) in blocking solution was added drop-wise to cover each section. The slides were placed inside the humidified chamber/incubator for 30 minutes and then placed at 4°C overnight. On the following day, the slides were washed in PBS followed by incubation with a 1/100 dilution of goat anti-mouse AP-conjugated Ab (Oncogene Research Products, Cambridge, Mass) for 2 hours. After extensive washing in PBS, the slides were washed with AP buffer (10 mM Tris-HCl (pH 9.5), 10 mM NaCl, and 1 mM MgCl 2 ) for 10 minutes before being blotted dry and covered with the nitroblue tetrazolium (NBT)/ 5-bromo-4-chloro-3-indolyl phosphate (BCIP) staining solution (AP buffer supplemented with 0.3 mg/mL of NBT and 0.175 mg/mL of BCIP and 2 drops of levamisole per 10 mL). The box was immediately placed in the dark at 4°C and allowed to develop overnight.
RESULTS
Rat RT2 cells express low levels of CD
BrdC is an HP that is 10-to 100-fold more specific for HSV-TK than for cellular TK 13, 14 and is incorporated into DNA as BrdU (Fig 1) . Using BrdC in combination with HSV-TK, one can therefore capitalize on the extensive preclinical and clinical experience that has accumulated over the past 20 years using BrdU and IdU as radiosensitizer, as well as take advantage of wellestablished tools, such as anti-BrdU Ab, 15 for the analysis of treated tumors. The mechanism by which BrdU kills cells in combination with radiation is likely to proceed via breaks in DNA. 16, 17 The specific utilization of BrdC by HSV-TK is highly dependent upon cellular CD levels. 13 If CD levels are high, BrdC is converted into BrdU that is incorporated into DNA irrespective of whether or not HSV-TK is present (Fig 1) . Rat cells are generally low in CD, whereas human cells have higher levels. 18 CD is inhibited by tetrahydrouridine (THU), a clinically approved drug that prevents the conversion of BrdC to BrdU; 19 THU has been used in clinical trials for improving the treatment of leukemia with 1-␤-Darabinofuranosyl cytosine. 20 -22 Therefore, we first tested the RT2 cells for CD activity and compared these with the CD levels in human HeLa cells. We found that extracts from RT2 cells have Ͼ20-fold lower levels of CD compared with HeLa cells (Fig 2A) . Protein extracts from RT2 cells produced specific activities of Ͻ1 nmol/mg protein per minute, whereas extracts from HeLa cells gave a specific activity of 19.3 nmol/mg protein per minute. We also tested whether FBS or collected Fischer 344 rat sera had any CD activity, because RT2 cells exposed to BrdC in sera during in vitro and in vivo experimentation would result in significant conversion of BrdC to BrdU without any HSV-TK expressed. However, both of these sources of sera were low in CD activity (Fig 2B) . These results demonstrate that RT2 cells, Fischer 344 rat sera, and FBS are low in CD activity. Therefore, RT2 cells and the experimental conditions appear suitable for our studies.
Effective radiosensitization of RT2 cells infected with an adenovirus expressing HSV-TK and exposure to BrdC correlates with increased BrdU DNA incorporation and apoptosis RT2 cells were infected with either ADV-TK or Ad␤gal (at a multiplicity of infection (MOI) of ϳ100); after 24 hours, cells were exposed to 100 M BrdC overnight (ϳ15 hours). On the following day, the cells were exposed to 60 Co irradiation between 2 Gy and 12 Gy and then allowed to grow for 5 days, at which time cell viability was determined (Fig 3A) . We found that cells exposed to BrdC and infected with ADV-TK were significantly more radiosensitive than cells infected with Ad␤gal and exposed to BrdC. The sensitizer enhancement ratio (SER) value (SER ϭ slope of survival curve without BrdC/slope of survival curve with BrdC) was calculated to 2.3.
To examine the extent of BrdU incorporation into cellular DNA, we analyzed parallel cell samples by HPLC analysis. We found little to no BrdU incorporation (Ͻ1%) in either uninfected or Ad␤gal-infected cells exposed to BrdC and almost 24% incorporation in ADV-TK-infected and BrdC-treated cells (Fig 3B) . Be- BrdC is converted by HSV-TK to BrdCMP. BrdCMP in turn is converted by deoxycytidylate deaminase to BrdUMP, which contributes to the general nucleoside pool and is incorporated into DNA. A competing arm of the conversion of BrdC to BrdUMP, which decreases the specificity for HSV-TK, is the deamination of BrdC by CD to BrdU. BrdU can be converted by either cellular TK or HSV-TK to BrdUMP. CD is low in rat cells and can be efficiently inhibited by THU in human cells.
cause exposure of tumor cells to radiation or chemotherapeutic drugs results in necrotic or apoptotic cell death depending upon cell type, we also examined whether RT2 cells infected with ADV-TK and exposed to BrdC and radiation underwent apoptosis or necrotic cell death. We performed TUNEL assays of the same cell populations used above for the radiosurvival and BrdU DNA incorporation analyses. Figure 3C shows the results of the TUNEL assay of RT2 cells infected with either Ad␤gal or ADV-TK, exposed to BrdC, and irradiated with 4 Gy or left untreated; Figure 3D summarizes these results. We found that the combination of ADV-TK infection and exposure to BrdC induced apoptosis at a rate of ϳ11% as measured at 20 hours posttreatment. Radiation alone did not significantly increase apoptosis levels (Ͻ1%), whereas the combination of radiation with BrdC and ADV-TK infection more than doubled (23%) the level of apoptosis compared with ADV-TK/BrdC treatment alone.
Because the concentration of BrdC in the sera of experimental animals does not reach 100 M, we subsequently tested whether significant effects on survival and apoptosis could be seen with a lower BrdC concentration, which is more likely achieved in vivo. Again, RT2 cells were infected with ADV-TK followed by exposure to 10 M BrdC overnight (ϳ15 hours) and then grown for 5 days. This experiment resulted in an SER of 1.4 (Fig 4) . To see whether this smaller, yet significant, response could also be attributed to apoptosis, we carried out a more extensive dose and time course experiment with ADV-TK-and Ad␤gal-infected cells. We varied the time of drug exposure between 24 and 48 hours, as well as the time between irradiation and apoptosis assay. The data shown in Figure 5 demonstrate that BrdC at 10 M significantly increased apoptosis in ADV-TK-infected RT2 cells compared with Ad␤gal-infected cells, an effect which was time-dependent (compare Fig 5, A, B, and C) . The longer time of exposure to BrdC (24 vs. 48 hours) and the longer time (5 vs. 20 hours) after irradiation, the greater the level of apoptosis. However, potentiation (1.5-to 2-fold) of apoptosis with 4 Gy of radiation was observed under each condition. Furthermore, exposure of cells to BrdU, which is incorporated into DNA irrespective of whether or not HSV-TK is present, resulted in some apoptosis by itself, and this effect increased with time. Radiation also potentiated the BrdU treatment ( Fig 5B) . As expected, the effect of using 10 M BrdC or BrdU produced lesser effects on apoptosis than were observed after treatment with 100 M (Fig 3) .
Taken together, these results demonstrate significant radiosensitization of RT2 cells with ADV-TK and BrdC that correlates with the incorporation of BrdU into cellular DNA. Most importantly, whereas radiation alone barely produced significant increases in apoptosis, treatment with ADV-TK and BrdC did. Most significantly, radiation potentiated apoptosis 1.5-to 2-fold in combination with ADV-TK and BrdC. These results suggest that chemical radiosensitization of RT2 cells with HSV-TK/BrdC is an efficient way of triggering apoptotic cell death that is reflected in the extent of cell survival and, thus, appears to be a major cause of cell death after this treatment.
Optimization of adenovirus-mediated gene delivery by slow, rate-controlled positive pressure infusion To investigate the in vivo efficacy of adenovirus infusion, we first established conditions for growing soft tissue Co. After 5 days, the cells were trypsinized and stained with trypan blue; live cells were counted with a hemocytometer. Survival fractions were calculated as the fraction of live cells after each treatment compared with infected but otherwise untreated cells. B: Increased incorporation of BrdU into RT2 DNA after infection with ADV-TK and BrdC exposure. A portion of each cell population from (A) was taken for DNA extraction, hydrolysis, and HPLC analysis. ‫,ء(‬ Ͻ1% BrdU incorporation). C: Apoptosis assay of adenovirus-infected and BrdC-treated RT2 cells. A portion of each cell population from (A) was taken for TUNEL assay 20 hours after 4 Gy irradiation. Fluorescence microscopy images of apoptotic (fluorescein isothiocyanate-stained) RT2 cells counterstained with propidium iodide are shown. a: Ad␤gal-infected, no irradiation; b: Ad␤gal-infected, exposed to BrdC but without any irradiation; c: Ad␤gal-infected, exposed to BrdC and irradiated with 4 Gy; d: ADV-TK-infected, exposed to BrdC but without any irradiation; e: ADV-TK-infected, exposed to BrdC and irradiated with 4 Gy; f: Same as (e), but at a higher magnification. White arrows depict apoptotic cells. D: Quantification of the apoptosis levels in (C). At least 300 cells were counted ‫,ء(‬ Ͻ1% apoptosis).
RT2 tumors in syngeneic Fischer 344 rats. We found that a s.c. injection of 10 6 RT2 cells in a volume of 100 L generated tumors in a timely fashion for further virus infusion studies. Tumors were allowed to grow to 8 -10 mm in diameter (7-10 days), doubling in size approximately every 2 days (data not shown), and were then infused with the same dose of Ad␤gal but using different conditions by altering the rate and volume of infusion. To achieve uniform and reproducible results, we employed a slow and rate-controlled positive pressure pump that we have used previously to deliver antisense oligonucleotides into the brain of Fischer 344 rats. 23 We found that 5 ϫ 10 9 PFU of Ad␤gal in a volume of 150 L and infused at a rate of 1 L/minute was the most efficient condition for virus delivery compared with the same dose of virus in either 50 or 3 ϫ 50 L, as determined by ␤-gal staining of tumor sections (Fig 6) . Using this procedure, we were able to achieve 40% infection of the tumor, whereas 50 and 3 ϫ 50 L produced 5% and 25% infection, respectively. We also found that slower infusion rates (Ͻ1 L/minute) did not result in significantly improved infection levels (data not shown). This result demonstrates that a relatively slow infusion of Ad␤gal in larger volumes over a longer period of time (2.5 hours) is more effective than infusion of smaller volumes with the same dose of virus.
Incorporation of BrdC, as BrdU, into tumors infused with ADV-TK and exposed to BrdC RT2 tumors were infused with either ADV-TK or Ad␤gal, and an osmotic pump delivering BrdC was inserted s.c. on the back of the animal. The animal was sacrificed after 3 days, and tumors were sectioned and stained with anti-BrdU Ab to detect incorporated BrdU. We found that the ADV-TK-infused tumor produced Figure 4 . Radiosensitization of RT2 cells in vitro at a lower concentration of BrdC. RT2 cells were infected with ADV-TK as described above, exposed to 10 M BrdC overnight (ϳ15 hours), irradiated, and subsequently diluted in microtiter plates and allowed to grow for 5 days, at which time an MTT assay was carried out. Growth retardation was calculated as the fraction of infected but otherwise untreated cells. Statistical analysis was carried out using the unpaired, one-tailed, Student's t test. P values were .0060 and .0068 at 4 and 8 Gy, respectively. Apoptosis levels of cells exposed to low concentrations of BrdC or BrdU. RT2 cells infected with either Ad␤gal or ADV-TK (at an MOI of ϳ50) were exposed to BrdC or BrdU at 10 M for either 24 or 48 hours at 2 days postinfection. Parallel samples were irradiated with 4 Gy, and cells were collected in triplicate for apoptosis assay at either 5 or 20 hours postirradiation. A: Cells that were exposed to BrdC or BrdU for 24 hours, irradiated (4 Gy), and subsequently processed for apoptosis assay 5 hours after ionizing radiation (IR). B: Cells exposed to BrdC or BrdU for 24 hours, irradiated (4 Gy), and subsequently processed for apoptosis assay 20 hours after IR. C: Cells exposed to BrdC or BrdU for 48 hours, irradiated (4 Gy), and subsequently processed for apoptosis assay 20 hours after IR. Statistical analysis was carried out using the unpaired, one-tailed, Student's t test. ‫,ء‬ P Ͻ .033; ‫,ءء‬ P Ͻ .028. cells that stained dark blue, indicating specific incorporation of BrdU into DNA (Fig 7A) . No such dark cells were detected in the tumor infused with Ad␤gal, which had been stained with X-Gal to detect ␤-gal before anti-BrdU Ab staining (Fig 7B) . This result demonstrates that we were able to achieve significant incorporation of BrdU into tumor DNA at 3 days after BrdC exposure; this incorporation was detected in at least 10% of cells within a given microscope field. This incorporation was specific for the ADV-TK-infused tumor, because we were unable to detect any anti-BrdUstained cells in sections derived from the Ad␤gal-infused tumor. In support of this finding, HPLC analysis of DNA extracted from other tumors treated in a similar fashion produced BrdU incorporation levels of between 11% and 22%, whereas control tumors produced Ͻ1% incorporation (data not shown).
Infusion of RT2 tumors with ADV-TK and exposure to BrdC results in significant tumor regression after radiation compared with controls To examine whether RT2 tumors infused with ADV-TK and exposed to BrdC behaved any differently than controls when exposed to radiation, we again established RT2 tumors in animals and infused them with either ADV-TK or Ad␤gal virus. Some animals received BrdC, whereas others did not and served as controls. At 5 days after virus infusion and osmotic pump implantation, tumors were irradiated with 5 Gy twice daily for 3 consecutive days. Tumor size was measured starting on day 1, and relative tumor volume (V t /V o ) was calculated and taken as a measure of tumor growth/regression. We found that on day 6, tumors infused with ADV-TK and exposed to BrdC followed by 30 Gy of radiation had regressed to ϳ40% of the volume on day 1 and were significantly (P Ͻ .001) smaller than tumors infused with ADV-TK and exposed to BrdC but not irradiated (Fig  8) . Most importantly, tumors infused with ADV-TK and exposed to BrdC and radiation produced a significant (P Ͻ .009) ϳ2-fold reduction in tumor volume compared with tumors infused with Ad␤gal and similarly exposed to BrdC and radiation. Without radiation, tumors infused with ADV-TK but without BrdC exposure did not behave any differently than tumors infused with Ad␤gal (data not shown), suggesting that the ADV-TK and Ad␤gal viruses did not produce any tumor regression by themselves. This result clearly demonstrates that ADV-TK in combination with BrdC significantly radiosensitizes RT2 tumors as determined by tumor regression analysis.
DISCUSSION
The clinical strategy underlying the use of HPs as radiosensitizers is to capitalize on the relatively rapid Figure 7 . Specific incorporation of BrdU in ADV-TK-infused RT2 tumors exposed to BrdC in vivo. Tumors were established in the hind legs of Fischer 344 rats. When the tumors reached a size of ϳ10 mm, one tumor was infused with ADV-TK and the other with Ad␤gal. After infusion, an osmotic pump with 50 mg/mL of BrdC was inserted s.c. on the back of the animal. The animal was sacrificed 3 days later, and the tumors were excised, frozen, and sectioned. The sections obtained from the Ad␤gal-infused tumor were stained with X-Gal to detect ␤-gal ϩ cells. Sections that demonstrated ␤-gal staining and sections obtained from ADV-TK-infused tumors were then incubated with anti-BrdU mouse immunoglobulin G Ab followed by goat anti-mouse immunoglobulin G conjugated to AP and exposed to BCIP/NBT as described in Materials and Methods. We found that only ADV-TK-infused tumors gave a positive signal (A); Ad␤gal-infused tumors did not (B). Black arrows depict AP-stained cells, which are indicative of increased incorporation of BrdU. The darker cells in (B) are ␤-gal ϩ cells.
cell growth of the tumor with respect to surrounding normal tissues and to achieve a greater degree of thymidine replacement in the tumor. 2 In turn, this replacement should increase the therapeutic window for radiation therapy. HPs have been used for many years as radiosensitizers, and more recently for the treatment of nonresectable high-grade head and neck tumors and high-grade gliomas. 24, 25 Although head and neck sarcomas were highly susceptible to IdU infusion and radiotherapy, achieving a 60% local control rate, the results with high-grade gliomas have been disappointing. 6 The responsiveness of head and neck tumors to HP radiosensitization is directly related to the extent of IdU DNA incorporation (i.e., the more incorporation of HPs into DNA, the better the radiosensitization). 3, 25 Because of the relatively poor response of gliomas to traditional radiotherapy and to radiosensitizers, alternative and more effective approaches to treat this incurable disease would be highly desirable.
The mechanism by which HPs radiosensitize cells is believed to involve incorporation of the HPs into the DNA as a substitute for thymidine. 2 HPs enter the cellular nucleoside pool through the pyrimidine salvage pathway with the help of TK and then compete with deoxyribosylthymine 5Ј-triphosphate for subsequent phosphorylation and incorporation into DNA. 1 Once they are part of the DNA, the HPs render the DNA more susceptible to radiation-induced double-stranded DNA breaks, which eventually result in lethality. 17 In addition, the presence of HPs in the DNA increases the fixation of potentially lethal damage. 16 The actual chemical reactions underlying radiosensitization by HPs are not known but are believed to involve dehalogenation followed by base hydrolysis and strand breakage. 2, 26 Typical SER values seen with HPs are in the range of 1-3, with the higher values obtained in tissue culture experiments. 2, 3 One drawback of using either BrdU or IdU as tumor radiosensitizers is the lack of discrimination between tumor and normal cells (i.e., these nucleosides are phosphorylated as well by cellular TK as they are by HSV-TK, and BrdU/IdU is incorporated into DNA by both proliferating normal and tumor cells). To take full advantage of the HSV-TK approach for tumor radiosensitization, it is necessary to use drugs that can only be used by HSV-TK. In sharp contrast to BrdU, BrdC is more specific (10-to 100-fold) for HSV-TK than for cellular TK 13, 14 and is not converted to BrdC monophosphate (BrdCMP) by cellular deoxycytidine kinase because of a very high K m (400 M) compared with deoxycytidine (K m of ϳ2 M).
13,27 Therefore, BrdC is specifically converted by HSV-TK into BrdCMP and then into BrdU monophosphate (BrdUMP) by cellular deoxycytidylate deaminase, which is abundant in proliferating cells and in tumors. However, in a parallel and opposing metabolic pathway, BrdC is converted into BrdU by cellular CD. 13 Using rats for our studies, we avoided any problems associated with higher CD levels, because rat cells, including RT2 cells, are unusually low in CD. 18 For this strategy to also work in human cells, THU 28 or another inhibitor will most likely need to be used to inhibit CD and to maintain the therapeutic differential between cells that express HSV-TK and those that do not.
Recently, it was demonstrated that rat glioma cells transduced with a retrovirus expressing HSV-TK were specifically radiosensitized (SER 1.4 -1.6) by exposure to either 5-(2-bromovinyl)-2-deoxyuridine or acyclovir, both of which are highly specific anti-herpetic drugs, in vitro and in vivo. 29 -31 These cells were permanently altered to express HSV-TK and were implanted directly into rat brains to assess the in vivo effects. 29 -31 The results from our study with HSV-TK and BrdC, which produced SERs of between 1.4 and 2.3, as well as the results from these other studies 29 -31 suggest that HSV-TK-mediated radiosensitization using different anti-herpetic drugs is an efficient combination modality for the treatment of glioma. However, only by using BrdC can one take full advantage of the extensive preclinical and clinical experience that has accumulated over the past two decades using BrdU and IdU as radiosensitizers.
Apoptosis is a common type of cell death when some, but not all, types of cells are exposed to chemotherapeutic drugs or to radiation. 32, 33 From a therapeutic standpoint, it would be desirable to trigger cells into apoptosis rather than necrosis to avoid the inflammatory responses associated with the latter. 32 In this study, we demonstrated that the majority of cells exposed to radiation and HSV-TK in combination with BrdC undergo apoptosis, whereas cells exposed to radiation alone show only a small increase in apoptosis. Most importantly, radiation potentiates the apoptotic effect of the HSV-TK/BrdC treatment. The survival data we obtained with Figure 8 . Increased tumor regression after treatment with ADV-TK/ BrdC followed by fractionated radiation. RT2 tumors were established in Fischer 344 rats and infused with either ADV-TK or Ad␤gal. Immediately after infusion, mini osmotic pumps holding BrdC were implanted in some of the animals. At 5 days after infusion and pump implantation, some tumors received 2 ϫ 5 Gy every day for 3 consecutive days. Tumor size was determined with calipers, and average volume ratios were calculated based on the initial tumor volume. An average of six tumors was used for each condition. Significant differences ‫,ء(‬ ‫)ءء‬ are indicated.
HSV-TK/BrdC treatment and radiation and the corresponding BrdU incorporation values are in excellent agreement with previous results from in vitro radiosensitization studies using hamster V-79 cells and HPs, 3, 34 suggesting that the mechanism by which HSV-TK/BrdC radiosensitizes RT2 cells is by incorporation of BrdU into DNA, presumably resulting in DNA strand breaks that lead to apoptotic cell death. An apoptotic mechanism of cell death has also been suggested for HSV-TKmediated killing of gliomas using the drug GCV. 35, 36 We also demonstrate that RT2 tumors are rendered significantly more sensitive to radiation after infusion with ADV-TK and exposure to BrdC compared with control-treated tumors, as determined by tumor regression. The RT2 tumor model used in this study is a syngeneic model that provides normal immune functions, which may be important in the overall response of tumors to cancer gene therapy. A previous study suggested that an intact immune system is necessary to elicit an efficient antitumoral response during HSV-TK cancer gene therapy in mice. 37 Furthermore, the apoptotic cell death of human glioma cells observed in vitro through "bystander" effects of HSV-TK/GCV treatment may require an intact immune system in vivo. 35 We find no indication that either ADV-TK or Ad␤gal elicited any immune response in tumors by themselves compared with control tumors, because tumors infused with virus did not grow any differently than tumors that were not infused (data not shown). This finding suggests that the virus itself is not triggering the antitumoral effect in these immune-competent rats. Furthermore, and very importantly, multiple tumors did not result in any growth reduction of individual tumors (data not shown), suggesting that these animals do not elicit any tumor immune response with increasing tumor load.
The use of a slow positive pressure device, delivering virus in a very controlled and reproducible fashion, is critical for the success of these types of studies. We find that delivering virus at Յ1 L/minute over longer periods of time and using relatively large volumes is most efficacious; however, these requirements, in our opinion, are not very well met by manual delivery. This novel technology could easily be adapted to any kind of gene delivery.
In summary, we have demonstrated that HSV-TK expressed from an adenovirus vector in combination with BrdC significantly radiosensitizes RT2 cells and tumors in vitro and in vivo. Our in vitro data suggest that the major cause of cell death is by apoptosis. We also demonstrate efficient and reproducible virus infusion into tumors by using a slow, rate-controlled positive pressure infusion device, which potentially could be modified for the delivery of any type of virus vector into tumors. Importantly, the HSV-TK/BrdC approach that we describe is expected to radiosensitize cells by a known mechanism (i.e., by the incorporation of BrdU into DNA) that capitalizes on extensive clinical experience. Future studies will focus on whether this approach is also effective in human cells and tumors.
